Nektar Therapeutics (NKTR) Gross Margin (2016 - 2025)
Historic Gross Margin for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to 12.66%.
- Nektar Therapeutics' Gross Margin fell 416900.0% to 12.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 25.74%, marking a year-over-year decrease of 270100.0%. This contributed to the annual value of 57.28% for FY2024, which is 16100.0% down from last year.
- According to the latest figures from Q3 2025, Nektar Therapeutics' Gross Margin is 12.66%, which was down 416900.0% from 7.62% recorded in Q2 2025.
- In the past 5 years, Nektar Therapeutics' Gross Margin registered a high of 78.95% during Q3 2022, and its lowest value of 65.01% during Q1 2025.
- Its 5-year average for Gross Margin is 54.01%, with a median of 67.31% in 2023.
- Its Gross Margin has fluctuated over the past 5 years, first soared by 147300bps in 2024, then crashed by -1132300bps in 2025.
- Nektar Therapeutics' Gross Margin (Quarter) stood at 75.36% in 2021, then dropped by -5bps to 71.7% in 2022, then decreased by -22bps to 55.78% in 2023, then increased by 26bps to 70.51% in 2024, then tumbled by -82bps to 12.66% in 2025.
- Its Gross Margin stands at 12.66% for Q3 2025, versus 7.62% for Q2 2025 and 65.01% for Q1 2025.